Axonics Modulation Technologies Garners $38,500,000 Series B Funding

  • Feed Type
  • Date
    12/21/2015
  • Company Name
    Axonics Modulation Technologies
  • Mailing Address
    7575 Irvine Center Drive Irvine, CA 92618 USA
  • Company Description
    Axonics, based in Irvine, Calif., is a company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
  • Website
    http://www.axonicsmodulation.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to conduct a multi-center clinical study in Overactive Bladder patients anticipated to begin in early 2016 in Europe and North America
  • M&A Terms
  • Venture Investor
    Advent Life Sciences
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    Edmond de Rothschild Investment Partners
  • Venture Investor
    NeoMed Management
  • Venture Investor
    Legend Capital
  • Venture Investor
    Undisclosed
  • Venture Investor
    The Alfred E. Mann Foundation

Trending on Xconomy